San Francisco, Calif. and Horsham, UK, 20 June 2019: endpoint Clinical, the leading global interactive response technology (IRT®) company, and Cmed Technology, the technology division of a full-service CRO with its encapsia clinical data suite, announced today a new interoperability in their clinical trial software systems. This revolutionary integration allows the power of IRT to be accessed through eSource, reducing site burden, the number of software systems used, and operational study costs.
“With both organizations focused on simplifying the management of complex trials, particularly oncology studies, it was a natural partnership to integrate our two state-of-the-art technology systems to provide sites with a more advanced and modern-day approach to clinical trial management,” says Vincent Puglia, Senior Director, Strategic Alliances, endpoint.
The new technology offering was designed by connecting endpoint’s leading-edge technology platforms, PULSE and DRIVE, with Cmed’s new dedicated web app, Inventory, further increasing the scope of its third generation clinical data suite encapsia.
“Although clinical trial designs become more complex over time, it shouldn’t mean that they get more challenging to manage. We need to provide all sites with technology that is intuitive and easy to use. With encapsia, site users no longer have the burden of using a separate IRT system. The most complex IRT tasks handled by endpoint’s IRT platform like managing subject data as well as randomization, inventory management, and drug dispensation can now be performed in real time using the single interface and unified database of encapsia. This revolutionary advancement not only benefits sites by saving them time and burden but also time and cost savings that carry through to the entire clinical study,” says Timothy Corbett-Clark, CTO, Cmed.
Site users see immediate benefits through this advanced technology by being able to perform all the tasks of an eCRF and IRT within the single user interface of encapsia, including:
As the complexities of clinical trials steadily increase, endpoint and Cmed are dedicated to enhancing their technologies further to minimize the burden on site staff and provide them with an optimal “consumer-like” experience.
endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. For the past decade, their customer-obsessed team of professionals have been continuously evolving their suite of technologies to help Sponsors achieve clinical trial success. Their dynamic IRT solution, PULSE ®, for patient randomization and management, site management, and drug supply management and leading-edge clinical supplies management tool, DRIVE, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. endpoint is headquartered in San Francisco, California, with offices across the US, EU, and Asia. www.endpointclinical.com
About Cmed and encapsia
encapsia is an innovative, powerful, next-generation clinical data suite that delivers a complete solution to gather and manage data in clinical trials and apply live insights and analytics on trial progress to inform and support management decisions. www.encapsia.com encapsia is developed by the technology division of Cmed Group, with headquarters in Horsham, UK plus offices in Durham NC, Cambridge MA, San Bruno CA and Timisoara, Romania. www.cmedresearch.com.
Call us from within the United States:
Calling from outside the United States?